Maze raises $190 million to advance precision medicine programs and platform

11 January 2022

California-based Maze Therapeutics, a company seeking to translate genetic insights into new precision medicines, has announced a $190 million financing.

Proceeds from the financing will be used to support advancement of the company’s nine precision medicines programs for both rare and common genetically defined diseases with high unmet need.

"The potential to generate a continuous stream of precision therapies in complex disease areas"These include Maze’s three most advanced programs, MZE001 for the treatment of Pompe disease, its APOL1 program for chronic kidney disease and ATXN2 for amyotrophic lateral sclerosis (ALS). The company expects MZE001 to enter the clinic in the first half of 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK